How to Pass CE Testing for LED Therapy Devices — A Practical Compliance Roadmap

CE marking is not a test you take once. It is a continuous compliance obligation that starts before the first prototype is built and continues for as long as the product is on the market. The manufacturers who struggle with CE testing are almost always the ones who treated it as a final checklist instead of a design principle from the beginning.

For LED therapy device manufacturers and their OEM partners, passing CE testing — and maintaining CE compliance — is one of the most important milestones in bringing a product to the European market. It is also one of the most commonly misunderstood aspects of the compliance process.

This article is written from the perspective of an LED therapy OEM manufacturer that has navigated EU MDR compliance for multiple product generations — sharing a practical, phase-by-phase roadmap for achieving and maintaining CE compliance for LED therapy devices.

CE Compliance Is Not One Test — It Is a System

Before getting into the process, the most important mental shift is this: CE compliance is not a single test that you pass or fail. It is a system of design controls, technical documentation, quality management, and ongoing obligations that together demonstrate your device meets the General Safety and Performance Requirements (GSPR) of EU MDR 2017/745.

Passing individual tests (electrical safety, EMC, biocompatibility) is part of the system — but tests alone do not constitute CE compliance. A device that passes every individual test can still fail CE compliance if the technical file is incomplete, the quality management system is inadequate, or the labeling does not meet the requirements.

With that framing established, here is the roadmap:

Phase 1: Design for Compliance — Before You Build Anything

The most effective CE compliance strategy starts at the design phase. Retrofitting a device to meet CE requirements is significantly more expensive and more time-consuming than designing for compliance from the start.

Step 1: Define the intended use and risk classification.

Under EU MDR 2017/745, the device classification determines almost everything that follows — the conformity assessment route, the level of notified body involvement, and the documentation requirements.

For LED therapy devices, the relevant rules are:

Rule 9: Devices that administer energy in a potentially hazardous way → Class IIa for devices delivering controlled light energy to the body
Rule 10: Devices for diagnosis or monitoring of non-life-threatening physiological processes → Class IIa in some cases

The classification is driven by the intended purpose — the language used in the Instructions for Use (IFU), the marketing materials, and the clinical evaluation. Using medical treatment language in the IFU or marketing will drive a higher classification than general wellness language.

Action: Before designing the product, define the intended use statement clearly and have it reviewed by a regulatory affairs specialist with EU MDR experience.

Step 2: Identify the applicable standards from the start.

For LED therapy devices, the applicable standards fall into several categories:

Category	Key Standards	Application
Electrical safety	IEC 60601-1 + IEC 60601-1-11 (home use)	All medical electrical devices
EMC	IEC 60601-1-2	Electromagnetic compatibility
Usability	IEC 62366-1	User interface design and usability engineering
Risk management	ISO 14971	Risk analysis and risk control
Biocompatibility	ISO 10993 series	Patient-contact materials (silicone, skin-contact surfaces)
Software	IEC 62304	Software lifecycle processes
Clinical evaluation	ISO 14155 + EU MDR Annex XIV	Clinical evidence for the claimed indications
Labeling	EU MDR Annex I, Chapter III	Label content, language, UDI requirements

Designing to these standards from the start — rather than testing to them at the end — reduces the cost and timeline of the conformity assessment significantly.

Step 3: Establish the quality management system in parallel with product development.

EU MDR requires ISO 13485:2016 as the quality management system foundation. The QMS should be established and operational before the technical file is compiled — because the technical file documentation processes (design controls, risk management, supplier qualification, production verification) all flow from the QMS.

For manufacturers who already have an ISO 13485 QMS certified by an accredited certification body, the EU MDR QMS requirement is largely met. For manufacturers building a new QMS, allow 6–12 months to establish and certify the system.

Phase 2: Build the Technical File

The technical file is the comprehensive documentation package that demonstrates your device meets the GSPR. For Class IIa devices, the technical file is submitted to a Notified Body for review.

The General Safety and Performance Requirements (GSPR) — Annex I to EU MDR — contains 23 chapters covering:

General requirements (benefit-risk analysis, risk management)
Chemical, physical, and biological properties
Infection and microbial contamination
Manufacturing and environmental properties
Devices with a measuring function
Protection against radiation
Devices with energy source (electrical safety, thermal safety)
Protection against electrical risks
Protection against mechanical and thermal risks
Protection against risks posed by devices for lay persons
Protection against harmful substances
Devices incorporating software
Devices with diagnostic or monitoring function
Performance and accuracy specifications
Clinical evaluation
Post-market surveillance
Information supplied by the manufacturer (labeling)
Traceability (UDI system)
And more…

The critical insight: Each of these 23 chapters must be addressed with evidence specific to your device. Generic test reports from a laboratory are part of the evidence — but they are not the only evidence required. Risk management files, design controls, clinical evaluation reports, and post-market surveillance plans are all part of the GSPR documentation.

Common mistake: Manufacturers who treat the technical file as a folder of test reports. The technical file is a structured demonstration of compliance — organized by GSPR chapter, with evidence mapped to each requirement.

Phase 3: Testing — What Is Needed and From Which Laboratory

For LED therapy devices, the laboratory testing program typically includes:

Electrical Safety — IEC 60601-1

The foundational test for all medical electrical devices. Testing must be conducted by an IECEE CB Scheme-accredited laboratory or a recognized national certification body. The test report must cover:

Clause 4 (general requirements)
Clause 8 (protection against electrical hazards)
Clause 9 (protection against mechanical hazards)
Clause 11 (protection against excessive temperatures and fire)
Clause 14 (accuracy of operating controls and instruments)
Clause 17 (protection against emitted radiation)
Clause 23 (protection against hazards of start-up)

For LED therapy masks intended for home use, IEC 60601-1-11 (requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment) is also required. This standard addresses usability considerations specific to lay users operating the device without professional supervision.

Electromagnetic Compatibility — IEC 60601-1-2

Tests both emissions (does the device interfere with other equipment?) and immunity (is the device affected by electromagnetic disturbances in its environment?). Required for all medical electrical devices. Must be conducted at an accredited EMC laboratory.

Biocompatibility — ISO 10993 Series

For LED therapy masks, the relevant tests are:

ISO 10993-5: Cytotoxicity — does the skin-contact material cause cell death?
ISO 10993-10: Sensitization and irritation — does the material cause allergic reactions or skin irritation with repeated contact?

Testing must be conducted on the finished, sterilized (if applicable), and packaged product — not just on raw material pellets. The silicone formulation may be biocompatible; the cured, finished silicone part with any additives or colorants may not be. Test the finished part.

Software Testing — IEC 62304

If the device includes software (intensity control, timing functions, mode selection, connectivity features), the software lifecycle processes must comply with IEC 62304. The software safety classification (Class A, B, or C) is determined by the potential harm posed by a software failure. For LED therapy devices with a display and user controls, the software is typically Class B (could cause non-serious injury or non-life-threatening harm).

Photobiological Safety — IEC 62471 / IEC 62471-1

For LED devices, photobiological safety testing is required to classify the device under the lamp safety standard. This is particularly important for LED therapy masks — which are used close to the face and eyes. The risk group classification (Exempt, Risk Group 1, 2, or 3) must be declared on the product label. For home-use devices, Risk Group 1 (low risk) or Exempt is the preferred classification.

Phase 4: The Conformity Assessment Route

For Class IIa LED therapy devices, the conformity assessment route requires the involvement of a Notified Body.

A Notified Body is an organization designated by an EU member state government and accredited to assess medical device technical files against the EU MDR requirements. The Notified Body is not the regulator — it is an accredited third party that acts on behalf of EU competent authorities.

The process:

The manufacturer compiles the complete technical file
The manufacturer submits the technical file to the Notified Body
The Notified Body reviews the file — assessing GSPR compliance, risk management, clinical evaluation, and labeling
The Notified Body conducts a quality management system audit of the manufacturer’s facility
If satisfied, the Notified Body issues a CE certificate
The manufacturer issues the Declaration of Conformity (DoC) and applies the CE mark

Timeline: 4–9 months for initial Class IIa certification, depending on the completeness of the technical file and the responsiveness of the manufacturer to Notified Body questions.

Ongoing obligation: Annual surveillance audits by the Notified Body. The CE certificate is not permanent — it must be maintained through ongoing QMS compliance and periodic PSUR updates.

Phase 5: Maintaining CE Compliance After Market Entry

CE compliance is not a one-time event. EU MDR imposes ongoing obligations that continue for the entire market life of the device.

Post-Market Surveillance (PMS): A systematic process to collect, document, and analyze post-market data about the device. For Class IIa devices, this includes:

Monitoring of customer complaints and adverse events
Analysis of returned products and failure data
Periodic review of the risk management file in light of new data

Periodic Safety Update Report (PSUR): For Class IIa devices, a PSUR must be updated at least every two years and submitted to the Notified Body. The PSUR summarizes the PMS data, any corrective actions taken, and any updates to the benefit-risk analysis.

Vigilance reporting: Serious adverse incidents occurring in the EU market must be reported to the relevant competent authority within 15 days (or 2 days for serious public health threats). This is a legal obligation — not optional.

Technical file updates: If the device is modified (hardware change, software update, materials change, labeling change), the technical file must be updated and the change must be evaluated against the original risk assessment. Significant changes may require re-notification to the Notified Body.

EUDAMED registration: The European database requires ongoing updates for device registration, UDI data, and adverse event reporting.

Common CE Testing Mistakes — And How to Avoid Them

Mistake 1: Testing at the wrong stage. Testing too late — after the design is finalized — creates the risk that test failures require design changes that are expensive and time-consuming to implement. Build and test prototypes early in the development cycle to catch compliance gaps before the production design is locked.

Mistake 2: Using generic test reports instead of device-specific evidence. A test report for “LED panel general lighting” does not satisfy IEC 60601-1 for an LED therapy mask. The test must be conducted on the actual device — the specific model, the specific enclosure, the specific skin-contact configuration. Generic test reports are not acceptable evidence for EU MDR compliance.

Mistake 3: Underestimating biocompatibility testing requirements. Testing the raw silicone material is not the same as testing the finished device component. The curing process, any additives, colorants, or surface treatments applied to the silicone may change its biocompatibility profile. Always test the finished, processed component that will be in contact with the user.

Mistake 4: Ignoring IEC 60601-1-11 for home-use devices. If the LED therapy mask is intended for home use (without professional supervision), IEC 60601-1-11 is required in addition to the base IEC 60601-1 standard. This standard covers usability considerations specific to lay users — including instructions, labeling adequacy, and protection against hazards that may arise from incorrect use in the home environment.

Mistake 5: Treating the CE mark as the end of compliance. CE marking is market access — it is the beginning of ongoing compliance obligations, not the end. Post-market surveillance, PSUR updates, vigilance reporting, and Notified Body surveillance audits all continue for the device’s market life. Manufacturers who treat CE as a one-time event create significant compliance risk.

How to Pass CE Testing — Common Questions

Q1: We already have IEC 60601-1 test reports from a laboratory for a previous product. Can we use those reports for a new LED therapy device?

In most cases, no. IEC 60601-1 test reports are device-specific — the test is conducted on the specific device model, with its specific enclosure, components, and circuit design. If the new device has a different enclosure, different LED configuration, different battery system, different controls, or any change to the hardware that could affect electrical safety, the test report from the previous device is not applicable. The exception: if the new device is a variant of the same base design with only cosmetic or non-safety-relevant changes, the Notified Body may accept a justified extrapolation — but this must be formally documented and justified in the technical file.

Q2: We are an overseas manufacturer. What additional requirements apply for CE marking?

Non-EU manufacturers must appoint a European Authorized Representative (EAR) — a legal entity located in the EU that is named on the CE label and holds the technical file on behalf of the manufacturer. The EAR is the manufacturer’s point of contact for EU competent authorities and is responsible for ensuring the manufacturer fulfills their EU MDR obligations. The EAR is not a simple registration agent — they have legal responsibility for device compliance. Choosing an EAR with medical device regulatory experience is essential.

Q3: Our device failed IEC 60601-1 testing. What is the typical process for resolving the failure and re-testing?

The process: (1) Review the test report carefully — it will specify the exact clause that failed and the conditions under which the failure occurred. (2) Perform a root cause analysis — was the failure a design deficiency, a manufacturing variance, or a test setup issue? (3) Engage your design team and an IEC 60601-1 specialist to identify the corrective action — this may be a hardware change (additional insulation, modified enclosure, changed component), a design change (revised wiring routing, updated creepage/clearance distances), or a manufacturing process change. (4) Verify the corrective action through design analysis or simulation before re-testing — re-testing is expensive, so confirm the fix is sound before committing to a re-test. (5) Conduct a focused re-test on the specific failed clause only — full re-testing of the entire standard is not always necessary if the scope of the corrective action is limited. (6) Update the technical file with the corrected design and the revised test report.

This article is written from the perspective of an LED therapy OEM manufacturer with experience in EU MDR Class IIa conformity assessment. The compliance roadmap reflects current EU MDR 2017/745 requirements and applicable harmonized standards. Regulatory requirements are subject to change — always verify current requirements with a qualified regulatory affairs specialist before initiating a conformity assessment.